ELVN-001 A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia (Aktiv)
H3 Biomedicine Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 (Aktiv)
ML DS 2018 Phase II/III Clinical Trial for the Treatment of Myeloid Leukemia in Children with Down Syndrome 2018 (Aktiv)
Novartis DFV890 A phase 1b, open label, multi-center, dose optimization and dose expansion study to assess the safety and efficacy of DFV890 in adult patients with myeloid diseases. (Aktiv)
Ruxo-BEAT Ruxolitinib im Vergleich zur besten verfügbaren Therapie in Patienten mit Hoch-Risiko Polycythemia vera oder Hoch-Risiko Essentieller Thrombozythämie – Die RUXO-BEAT Studie (Aktiv)